Clinical Guidelines

ACG Clinical Guideline: Diagnosis and Management of Pancreatic Cysts

  • The American Journal of Gastroenterology volume 113, pages 464479 (2018)
  • doi:10.1038/ajg.2018.14
  • Download Citation
Received:
Accepted:
Published:

Abstract

Pancreatic cysts are very common with the majority incidentally identified. There are several types of pancreatic cysts; some types can contain cancer or have malignant potential, whereas others are benign. However, even the types of cysts with malignant potential rarely progress to cancer. At the present time, the only viable treatment for pancreatic cysts is surgical excision, which is associated with a high morbidity and occasional mortality. The small risk of malignant transformation, the high risks of surgical treatment, and the lack of high-quality prospective studies have led to contradictory recommendations for their immediate management and for their surveillance. This guideline will provide a practical approach to pancreatic cyst management and recommendations for cyst surveillance for the general gastroenterologist.

  • Subscribe to The American Journal of Gastroenterology for full access:

    $870

    Subscribe

Additional access options:

Already a subscriber?  Log in  now or  Register  for online access.

References

  1. 1.

    , , et al. High prevalence of pancreatic cysts detected by screening magnetic resonance imaging examinations. Clini Gastroenterol Hepatol 2010;8:806–11.

  2. 2.

    , , et al. Prevalence of incidental pancreatic cysts in the adult population on MR imaging. Am J Gastroenterol 2010;105:2079–84.

  3. 3.

    , , . American gastroenterological association technical review on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. Gastroenterology 2015;148:824–48.

  4. 4.

    , , et al. The clinical relevance of the increasing incidence of intraductal papillary mucinous neoplasm. Clin Gastroenterol Hepatol 2012;10:555–8.

  5. 5.

    , , et al. Pancreatic cyst prevalence and the risk of mucin-producing adenocarcinoma in US adults. Am J Gastroenterol 2013;108:1546–50.

  6. 6.

    , , . AGA guidelines for the management of pancreatic cysts. Gastroenterology 2015;149:825.

  7. 7.

    , . Management of pancreatic cysts: the evidence is not here yet. Gastroenterology 2015;148:685–7.

  8. 8.

    , , et al. Progression of unresected intraductal papillary mucinous neoplasms of the pancreas to cancer: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2017;15:1509–20.

  9. 9.

    , , et al. Demographic features and natural history of intermediate-risk multifocal versus unifocal intraductal papillary mucinous neoplasms. Pancreas 2015;44:478–83.

  10. 10.

    , , et al. Pancreatic cyst disease: a review. JAMA 2016;315:1882–93.

  11. 11.

    , , et al. Mucinous cystic neoplasm of the pancreas: Is surgical resection recommended for all surgically fit patients? Pancreatology 2014;14:131–6.

  12. 12.

    , , et al. A review of mucinous cystic neoplasms of the pancreas defined by ovarian-type stroma: clinicopathological features of 344 patients. World J Surg 2006;30:2236–45.

  13. 13.

    , , et al. Serous cystic neoplasm of the pancreas: a multinational study of 2622 patients under the auspices of the International Association of Pancreatology and European Pancreatic Club (European Study Group on Cystic Tumors of the Pancreas). Gut 2016;65:305–12.

  14. 14.

    , , et al. A systematic review of solid-pseudopapillary neoplasms: are these rare lesions? Pancreas 2014;43:331–7.

  15. 15.

    , , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. Br Med J 2008;336:924–6.

  16. 16.

    , , et al. Incidental pancreatic cysts: clinicopathologic characteristics and comparison with symptomatic patients. Arch Surg 2003;138:427–34.

  17. 17.

    , , et al. Prospective preoperative determination of mucinous pancreatic cystic neoplasms. Surgery. 2002;132:628–33 discussion 633-4.

  18. 18.

    , , et al. Cystic lesions of the pancreas: clinical and pathologic review of cases in a five year period. J Pancreas 2010;11:358–64.

  19. 19.

    , , et al. Cystic lesions of the pancreas: an appraisal of an aggressive resectional policy adopted at a single institution during 15 years. Am J Surg 2006;192:148–54.

  20. 20.

    , , . Cyst features and risk of malignancy in intraductal papillary mucinous neoplasms of the pancreas: a meta-analysis. Clin Gastroenterol Hepatol 2013;11:913–21.

  21. 21.

    , , et al. Imaging of indeterminate pancreatic cystic lesions: a systematic review. Pancreatology 2013;13:436–42.

  22. 22.

    , , et al. Cystic neoplasms of the pancreas; findings on magnetic resonance imaging with pathological, surgical, and clinical correlation. Abdominal Imaging 2014;39:1088–101.

  23. 23.

    , , et al. Contrast-enhanced harmonic endoscopic ultrasonography for differential diagnosis of pancreatic cysts. Endoscopy 2016;48:35–41.

  24. 24.

    , , et al. Accuracy of preoperative workup in a prospective series of surgically resected cystic pancreatic lesions. Scand J Gastroenterol 2012;47:1056–63.

  25. 25.

    , , et al. Should we do EUS/FNA on patients with pancreatic cysts? The incremental diagnostic yield of EUS over CT/MRI for prediction of cystic neoplasms. Pancreas 2013;42:717–21.

  26. 26.

    , , et al. Accuracy of 18 F-FDG PET/CT, multidetector CT, and MR imaging in the diagnosis of pancreatic cysts: aprospective Single-Center Study. J Nucl Med 2015;56:1163–8.

  27. 27.

    , , et al. Incremental value of secretin-enhanced magnetic resonance cholangiopancreatography in detecting ductal communication in a population with high prevalence of small pancreatic cysts. Eur J Radiol 2015;84:575–80.

  28. 28.

    , , et al. Effects of comorbidities on outcomes of patients with intraductal papillary mucinous neoplasms. Clin Gastroenterol Hepatol 2015;13:1816–23.

  29. 29.

    , , et al. Risk for mortality from causes other than pancreatic cancer in patients with intraductal papillary mucinous neoplasm of the pancreas. Pancreas 2013;42:687–91.

  30. 30.

    , , et al. Validation of a combined comorbidity index. J Clin Epidemiol 1994;47:1245–51.

  31. 31.

    , . MDCT of acute mild (nonnecrotizing) pancreatiis: abdominal complications nd fate of fluid collections. AJR AM J Roentgenol 2008;190:643–9.

  32. 32.

    , , et al. Endoscopic ultrasound guided fine needle aspiration for the diagnosis of pancreatic cystic neoplasms: a meta-analysis. Pancreatology 2013;13:48–57.

  33. 33.

    , , et al. Diagnosis of pancreatic cystic neoplasms: a report of the cooperative Pancreatic Cyst Study. Gastroenterology 2004;126:1330–6.

  34. 34.

    , , . Cyst fluid analysis in the differential diagnosis of pancreatic cystic lesions: a pooled analysis. Gastrointest Endosc 2005;62:383–9.

  35. 35.

    , , et al. Endoscopic ultrasound-guided fine-needle aspiration of pancreatic cystic lesions provides inadequate material for cytology and laboratory analysis: initial results from a prospective study. Endoscopy 2011;43:585–90.

  36. 36.

    , , et al. Role of EUS-FNA-based cytology in the diagnosis of mucinous pancreatic cystic lesions: a systematic review and meta-analysis. Dig Dis Sci 2010;55:2756–66.

  37. 37.

    , , et al. Cyst fluid biomarkers for intraductal papillary mucinous neoplasms of the pancreas: a critical review from the international expert meeting on pancreatic branch-duct-intraductal papillary mucinous neoplasms. J Am Coll Surg 2015;220:243–53.

  38. 38.

    , , . Molecular analyses of aspirated cystic fluid for the differential diagnosis of cystic lesions of the pancreas: a systematic review and meta-analysis. Gastroenterol Res Pract 2016;2016 3546085. doi:10.1155/2016/3546085.

  39. 39.

    , , et al. Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc Natl Acad Sci US A 2011;108:21188–93.

  40. 40.

    , , et al. American Gastroenterological Association guidelines are inaccurate in detecting pancreatic cysts with advanced neoplasia: a clinicopathologic study of 225 patients with supporting molecular data. Gastrointest Endosc 2015;83:1107–17.

  41. 41.

    , , et al. A combination of molecular markers and clinical features improve the classification of pancreatic cysts. Gastroenterology 2015;149:1501–10.

  42. 42.

    , , et al. Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med 2011;3:92ra66.

  43. 43.

    , , et al. Next-generation sequencing adds value to the preoperative diagnosis of pancreatic cysts. Cancer Cytopathol 2016;125:41–7.

  44. 44.

    , , et al. Impact of next-generation sequencing on the clinical diagnosis of pancreatic cysts. Gastrointest Endosc 2016;83:140–8.

  45. 45.

    , , et al. Safety and efficacy of cytology brushings versus standard fine-needle aspiration in evaluating cystic pancreatic lesions: a controlled study. Endoscopy 2010;42:127–32.

  46. 46.

    , , et al. EUS-guided pancreatic cyst brushing: a comparative study in a tertiary referral centre. JOP 2010;11:163–9.

  47. 47.

    , , et al. Endoscopic ultrasonography-guided brushing increases cellular diagnosis of pancreatic cysts: a prospective study. Dig Liver Dis 2010;42:877–81.

  48. 48.

    , , et al. First assessment of needle-based confocal laser endomicroscopy during EUS-FNA procedures of the pancreas (with videos). Gastrointest Endosc 2011;74:1049–60.

  49. 49.

    , , et al. A novel approach to the diagnosis of pancreatic serous cystadenoma: needle-based confocal laser endomicroscopy. Endoscopy 2015;47:26–32.

  50. 50.

    , , et al. A pilot study of in vivo identification of pancreatic cystic neoplasms with needle-based confocal laser endomicroscopy under endosonographic guidance. Endoscopy 2013;45:1006–13.

  51. 51.

    , , et al. Diagnosis of pancreatic cysts: EUS-guided, through-the-needle confocal laser-induced endomicroscopy and cystoscopy trial: DETECT study. Gastrointest Endosc 2015;81:1204–14.

  52. 52.

    , , . Cyst carcinoembryonic antigen in differentiating pancreatic cysts: a meta-analysis. Dig Liver Dis 2013;45:920–6.

  53. 53.

    , , et al. Diagnostic yield of EUS-FNA-based cytology distinguishing malignant and benign IPMNs: a systematic review and meta-analysis. Pancreatology 2014;14:380–4.

  54. 54.

    , , et al. Cyst fluid telomerase activity predicts the histologic grade of cystic neoplasms of the pancreas. Clin Cancer Res 2016;22:5141–51.

  55. 55.

    , , et al. EUS-guided ethanol lavage does not reliably ablate pancreatic cystic neoplasms (with video). Gastrointest Endosc 2016;83:914–20.

  56. 56.

    , , et al. Is alcohol required for effective pancreatic cyst ablation? The prospective randomized CHARM trial pilot study. Endosc Int Open 2016;4:E603–7.

  57. 57.

    , , et al. Ethanol lavage of pancreatic cystic lesions: initial pilot study. Gastrointest Endosc 2005;61:746–52.

  58. 58.

    , , et al. New treatment for cystic tumors of the pancreas: EUS-guided ethanol lavage with paclitaxel injection. Gastrointest Endosc 2008;67:636–42.

  59. 59.

    , , et al. Septated cystic tumors of the pancreas: is it possible to treat them by endoscopic ultrasonography-guided intervention? Scand J Gastroenterol 2009;44:242–7.

  60. 60.

    , , et al. EUS-guided ethanol versus saline solution lavage for pancreatic cysts: a randomized, double-blind study. Gastrointest Endosc 2009;70:710–23.

  61. 61.

    , , . Ablation of pancreatic cystic lesions: the use of multiple endoscopic ultrasound-guided ethanol lavage sessions. Pancreas 2011;40:664–8.

  62. 62.

    , , et al. Endoscopic ultrasonography-guided ethanol lavage with paclitaxel injection treats patients with pancreatic cysts. Gastroenterology 2011;140:172–9.

  63. 63.

    , , et al. Alterations in cyst fluid genetics following endoscopic ultrasound-guided pancreatic cyst ablation with ethanol and paclitaxel. Endoscopy 2014;46:457–64.

  64. 64.

    , , et al. Endoscopic ultrasound guided radiofrequency ablation (EUS-RFA) for cystic neoplasms and neuroendocrine tumors of the pancreas. Gastrointest Endosc 2013;77:AB143–4.

  65. 65.

    , , et al. Patients with a resected pancreatic mucinous cystic neoplasm have a better prognosis than patients with an intraductal papillary mucinous neoplasm: a large single institution series. Pancreatology 2017;17:490–6.

  66. 66.

    , , et al. Clinicopathological aspects of small pancreatic cancer. Pancreas 2004;28:235–40.

  67. 67.

    , , et al. Minute carcinoma of the pancreas measuring 1 cm or less in diameter—collective review of Japanese case reports. Hepatogastroenterology 1999;46:8–15.

  68. 68.

    , , et al. The early detection of pancreatic cancer: What will it take to diagnose and treat curable pancreatic neoplasia? Cancer Res 2014;74:3381–9.

  69. 69.

    , , et al. Role of a Multidisciplinary Clinic in the Management of Patients with Pancreatic Cysts: A Single-Center Cohort Study. Ann Surg Oncol 2014;21:3668–74.

  70. 70.

    , , et al. Impact of nationwide centralization of pancreaticoduodenectomy on hospital mortality. Br J Surg 2012;99:404–10.

  71. 71.

    , , et al. Hospital volume and operative mortality in the modern era. Ann Surg 2014;260:244–51.

  72. 72.

    , , et al. Validating a simple scoring system to predict malignancy and invasiveness of intraductal papillary mucinous neoplasms of the pancreas. World J Surg 2010;34:776–83.

  73. 73.

    , , et al. Predictors of the presence of concomitant invasive ductal carcinoma in intraductal papillary mucinous neoplasm of the pancreas. Ann Surg 2010;251:70–5.

  74. 74.

    , , et al. Serum carcinoembryonic antigen and carbohydrate antigen 19-9 for prediction of malignancy and invasiveness in intraductal papillary mucinous neoplasms of the pancreas: A meta-analysis. Biomed Rep 2015;3:43–50.

  75. 75.

    , , et al. Acute pancreatitis in intraductal papillary mucinous neoplasms: A common predictor of malignant intestinal subtype. Surgery 2015;158:1219–25.

  76. 76.

    , , et al. Acute pancreatitis in patients operated on for intraductal papillary mucinous neoplasms of the pancreas: frequency, severity, and clinicopathologic correlations. Pancreas 2010;39:658–61.

  77. 77.

    , , et al. Early detection of sporadic pancreatic cancer: summative review. Pancreas 2015;44:693–712.

  78. 78.

    , , et al. Intraductal papillary mucinous neoplasms and the risk of diabetes mellitus in patients undergoing resection versus observation. J Gastrointest Surg 2015;19:1974–81.

  79. 79.

    , , et al. Predictors of malignant intraductal papillary mucinous neoplasm of the pancreas. J Clin Gastroenterol 2010;44:e224–9.

  80. 80.

    , , et al. Natural history of branch duct intraductal papillary mucinous neoplasms of the pancreas: a multicenter study in Japan. Pancreas 2011;40:364–70.

  81. 81.

    , , et al. Pancreatic ductal adenocarcinomas in long-term follow-up patients with branch duct intraductal papillary mucinous neoplasms. Pancreas 2010;39:36–40.

  82. 82.

    , , et al. Main-duct intraductal papillary mucinous neoplasms of the pancreas: clinical predictors of malignancy and long-term survival following resection. Ann Surg 2004;239:678–85 discussion 685-7..

  83. 83.

    , , et al. Cystic neoplasm of the pancreas: a Japanese multiinstitutional study of intraductal papillary mucinous tumor and mucinous cystic tumor. Pancreas 2004;28:241–6.

  84. 84.

    , , et al. Small (Sendai negative) branch-duct IPMNs: not harmless. Ann Surg 2012;256:313–20.

  85. 85.

    , , et al. Branch-duct intraductal papillary mucinous neoplasms: observations in 145 patients who underwent resection. Gastroenterology 2007;133:72–9 quiz 309-10..

  86. 86.

    , , et al. Evaluation of the guidelines for management of pancreatic branch-duct intraductal papillary mucinous neoplasm. Clin Gastroenterol Hepatol 2008;6:815–9 quiz 719.

  87. 87.

    , , et al. European experts consensus statement on cystic tumours of the pancreas. Dig Liver Dis 2013;45:703–11.

  88. 88.

    , , et al. A novel approach for selecting combination clinical markers of pathology applied to a large retrospective cohort of surgically resected pancreatic cysts. J Am Med Inform Assoc 2017;24:145–52.

  89. 89.

    , , et al. Measurement of pancreatic cystic lesions on magnetic resonance imaging: efficacy of standards in reducing inter-observer variability. Abdom Radiol 2016;41:500–7.

  90. 90.

    , , et al. MDCT of intraductal papillary mucinous neoplasm of the pancreas: evaluation of features predictive of invasive carcinoma. AJR Am J Roentgenol 2006;186:687–95.

  91. 91.

    , , et al. Usefulness of multidetector computed tomography for detecting protruding lesions in intraductal papillary mucinous neoplasm of the pancreas in comparison with single-detector computed tomography and endoscopic ultrasonography. Pancreas 2009;38:131–6.

  92. 92.

    , , et al. Intraductal papillary mucinous neoplasms of the pancreas: differentiation of malignant and benign tumors by endoscopic ultrasound findings of mural nodules. Ann Surg 2009;249:628–34.

  93. 93.

    , , et al. Comparative performance of MDCT and MRI with MR cholangiopancreatography in characterizing small pancreatic cysts. AJR Am J Roentgenol 2009;193:722–31.

  94. 94.

    , , et al. CT vs MRCP: optimal classification of IPMN type and extent. J Gastrointest Surg 2008;12:101–9.

  95. 95.

    , , et al. Prevalence of unsuspected pancreatic cysts on MDCT. Am J Roentgenol 2008;191:802–7.

  96. 96.

    , , et al. Cystic pancreatic neoplasms: observe or operate. Ann Surg 2004;239:651–7 discussion 657-9..

  97. 97.

    , , et al. Pancreatic cysts: depiction on single-shot fast spin-echo MR images. Radiology 2002;223:547–53.

  98. 98.

    , , et al. Managing incidental findings on abdominal CT: white paper of the ACR incidental findings committee. J Am Coll Radiol 2010;7:754–73.

  99. 99.

    , , et al. What is the best way to identify malignant transformation within pancreatic IPMN: a systematic review and meta-analyses. Clin Transl Gastroenterol 2015;6:e130.

  100. 100.

    , , et al. Intraductal papillary and mucinous tumors of the pancreas: accuracy of preoperative computed tomography, endoscopic retrograde pancreatography and endoscopic ultrasonography, and long-term outcome in a large surgical series. Gastrointest Endosc 1998;47:42–9.

  101. 101.

    , , et al. Intraductal papillary-mucinous tumors of the pancreas: differential diagnosis between benign and malignant tumors by endoscopic ultrasonography. Am J Gastroenterol 2001;96:1429–34.

  102. 102.

    , , et al. EUS in the evaluation of pancreatic cystic lesions. Gastrointest Endosc 2003;57:891–6.

  103. 103.

    , , . Intraductal papillary tumors of the pancreas: evaluation with endoscopic ultrasonography. Gastrointest Endosc 1998;48:164–71.

  104. 104.

    , , et al. Histologic and imaging features of mural nodules in mucinous pancreatic cysts. Clin Gastroenterol Hepatol 2012;10 (192-198): e2.

  105. 105.

    , , et al. Imaging features to distinguish malignant and benign branch-duct type intraductal papillary mucinous neoplasms of the pancreas: a meta-analysis. Ann Surg 2014;259:72–81.

  106. 106.

    , , et al. Cyst size indicates malignant transformation in branch duct intraductal papillary mucinous neoplasm of the pancreas without mural nodules. Pancreas 2010;39:232–6.

  107. 107.

    . Controversies in the management of pancreatic IPMN. Nat Rev Gastroenterol Hepatol 2011;8:56–60.

  108. 108.

    , , et al. High-grade dysplasia and adenocarcinoma are frequent in side-branch intraductal papillary mucinous neoplasm measuring less than 3 cm on endoscopic ultrasound. J Gastrointest Surg 2013;17:78–84 discussion p 84–5.

  109. 109.

    , , et al. Small-sized, flat-type invasive branch duct intraductal papillary mucinous neoplasm: a case report. Case Rep Gastroenterol 2013;7:449–54.

  110. 110.

    , , et al. Invasive carcinoma derived from "flat type" branch duct intraductal papillary mucinous neoplasms of the pancreas: impact of classification according to the height of mural nodule on endoscopic ultrasonography. J Hepatobiliary Pancreat Sci 2015;22:301–9.

  111. 111.

    , , et al. Cytology adds value to imaging studies for risk assessment of malignancy in pancreatic mucinous cysts. Ann Surg 2011;254:977–83.

  112. 112.

    , , et al. Accuracy of preoperative workup in a prospective series of surgically resected cystic pancreatic lesions. Scand J Gastroenterol 2012;47:1056–63.

  113. 113.

    , , et al. Branch duct intraductal papillary mucinous neoplasms: does cyst size change the tip of the scale? A critical analysis of the revised international consensus guidelines in a large single-institutional series. Ann Surg 2013;258:466–75.

  114. 114.

    , , et al. Evaluation of the Sendai and 2012 International Consensus Guidelines based on cross-sectional imaging findings performed for the initial triage of mucinous cystic lesions of the pancreas: a single institution experience with 114 surgically treated patients. Am J Surg 2014;208:202–9.

  115. 115.

    , , et al. Current recommendations for surveillance and surgery of intraductal papillary mucinous neoplasms may overlook some patients with cancer. J Gastrointest Surg 2015;19:258–65.

  116. 116.

    , , et al. Rapid growth rates of suspected pancreatic cyst branch duct intraductal papillary mucinous neoplasms predict malignancy. Dig Dis Sci 2015;60:2800–6.

  117. 117.

    , , et al. Cyst growth rate predicts malignancy in patients with branch duct intraductal papillary mucinous neoplasms. Clin Gastroenterol Hepatol 2011;9:87–93.

  118. 118.

    , , et al. Variability in measurements of pancreatic cyst size among EUS, CT, and magnetic resonance imaging modalities. Gastrointest Endosc 2010;71:945–50.

  119. 119.

    , , et al. Comparison of endoscopic ultrasonography, computed tomography, and magnetic resonance imaging for pancreas cystic lesions. Medicine 2015;94:e1666.

  120. 120.

    , , et al. MDCT vs. MRI for incidental pancreatic cysts: measurement variability and impact on clinical management. Abdom Radiol 2016;42:521–30.

  121. 121.

    , , et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010;467:1114–7.

  122. 122.

    , . Pancreatic cystic neoplasms: management and unanswered questions. Gastroenterology 2013;144:1303–15.

  123. 123.

    , , et al. The long term risk of malignancy in patients with branch duct intraductal papillary mucinous neoplasms of the pancreas. Pancreatology 2012;12:198–202.

  124. 124.

    , , et al. Low rates of malignancy and mortality in asymptomatic patients with suspected neoplastic pancreatic cysts beyond 5 years of surveillance. Clin Gastroenterol Hepatol 2016;14:865–71.

  125. 125.

    , , et al. Screening for colorectal cancer: updated evidence report and systematic review for the us preventive services task force. JAMA 2016;315:2576–94.

  126. 126.

    , , et al. Nature and management of pancreatic mucinous cystic neoplasm (MCN): a systematic review of the literature. Pancreatology 2016;16:1028–36.

  127. 127.

    , , et al. Locally advanced, unresectable pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2016;34:2654–68.

  128. 128.

    , , et al. Potentially curable pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2016;34:2541–56.

  129. 129.

    , , et al. Association of preoperative risk factors with malignancy in pancreatic mucinous cystic neoplasms: a multicenter study. JAMA Surg 2016;152:19–25.

  130. 130.

    , , et al. Is it necessary to follow patients after resection of a benign pancreatic intraductal papillary mucinous neoplasm? J Am Coll Surg 2013;216:657–65 discussion 665-7.

  131. 131.

    , , et al. Long-term prospective cohort study of patients undergoing pancreatectomy for intraductal papillary mucinous neoplasm of the pancreas: implications for postoperative surveillance. Ann Surg 2014;260:356–63.

  132. 132.

    , , et al. Prognostic impact of pancreatic margin status in the intraductal papillary mucinous neoplasms of the pancreas. Surgery 2010;148:285–90.

  133. 133.

    , , et al. Intraductal papillary mucinous neoplasm of the pancreas: clinical characteristics and treatment outcomes of 118 consecutive patients from a single center. J Hepatobiliary Pancreat Surg 2008;15:183–8.

  134. 134.

    , , et al. Intraductal papillary mucinous neoplasm (IPMN) with high-grade dysplasia is a risk factor for the subsequent development of pancreatic ductal adenocarcinoma. HPB 2016;18:236–46.

  135. 135.

    , , et al. Treatment strategy for main duct intraductal papillary mucinous neoplasms of the pancreas based on the assessment of recurrence in the remnant pancreas after resection: a retrospective review. Ann Surg 2014;259:360–8.

  136. 136.

    , , et al. Patterns of recurrence after resection of IPMN: who, when, and how? Ann Surg 2015;262:1108–14.

  137. 137.

    , , et al. Outcome of the pancreatic remnant following segmental pancreatectomy for non-invasive intraductal papillary mucinous neoplasm. HPB 2011;13:759–66.

  138. 138.

    , , et al. Intraductal papillary mucinous neoplasms of the pancreas: effect of invasion and pancreatic margin status on recurrence and survival. Ann Surg Oncol 2006;13:582–94.

  139. 139.

    , , et al. Long-term surveillance is necessary after operative resection for intraductal papillary mucinous neoplasm of the pancreas. Surgery 2016;160:306–17.

  140. 140.

    , , et al. Dysplasia at the surgical margin is associated with recurrence after resection of non-invasive intraductal papillary mucinous neoplasms. HPB 2013;15:814–21.

  141. 141.

    , , et al. Recurrences after surgical resection of intraductal papillary mucinous neoplasm of the pancreas: a single-center study of recurrence predictive factors. Pancreas 2012;41:137–41.

Download references

Acknowledgements

This guideline was produced in collaboration with the Practice Parameters Committee of the American College of Gastroenterology. The Committee gives special thanks to Walter G. Park, MD, who served as guideline monitor for this document.

Author information

Affiliations

  1. Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, Michigan, USA

    • Grace H Elta
  2. Division of Gastroenterology, Oregon Health and Sciences University, Portland, Oregon, USA

    • Brintha K Enestvedt
  3. Division of Gastroenterology, University of Virginia, Charlottesville, Virginia, USA

    • Bryan G Sauer
  4. Division of Gastroenterology, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA

    • Anne Marie Lennon

Authors

  1. Search for Grace H Elta in:

  2. Search for Brintha K Enestvedt in:

  3. Search for Bryan G Sauer in:

  4. Search for Anne Marie Lennon in:

Competing interests

Guarantor of the article: Grace H. Elta, MD, FACG.

Specific author contributions: Three authors (Drs. Elta, Enestvedt, and Lennon) planned the guideline, wrote portions of the manuscript, and edited the final version. Dr. Sauer provided the GRADE review.

Financial support: This work was supported by the American College of Gastroenterology.

Potential competing interests: None.

Corresponding author

Correspondence to Grace H Elta.